Last reviewed · How we verify
SGLT2i, beta blocker, ARNI, MRA, MTD
SGLT2i, beta blocker, ARNI, MRA, and MTD are marketed drugs developed by Brigham and Women's Hospital, with a key composition patent expiring in 2028. The key strength of these drugs lies in their diverse mechanisms of action, addressing multiple pathways in cardiovascular and metabolic diseases. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | SGLT2i, beta blocker, ARNI, MRA, MTD |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (PHASE4)
- LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: